Nighttime Halloween fun presents heightened risk for kids

Trick-or-treating is one of Halloween's favorite traditions, but the excitement of the night can quickly lead to injuries if ...
MedPage Today

Eye Manifestations in Crohn's; Night-Time Reflux Relief; IBS Behavioral Therapies

In a randomized trial, 1 day of octreotide infusion combined with endoscopic therapy proved noninferior to 5 days for acute esophageal variceal bleeding, both in terms of re-bleeding events and ...
India Today on MSN

How to manage sugar and fried foods during festivals, nutritionist explains

As Diwali brings a flood of sweets and snacks to every home, a nutrition expert shares how mindful eating, smart swaps, and ...

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients …

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early ...

Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer ...

Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in ...